Seventy-five percent of Novo Nordisk is accounted by the Health Care unit, which develops, manufactures, and sells pharmaceutical products and services. Primary in the unit’s products are drugs for diabetes patients. Novo Nordisk leads the world in diabetes care and holds a significant influence in the areas of growth disorders and women’s health care.
The other unit is called the Enzyme Business unit. This unit develops, manufactures and sells industrial enzymes. These industrial enzymes deal with industrial problems through biological solutions. Companies in various industries such as textile, starch and detergent manufacturers are the major patrons of Novo Nordisk, making it the leading industrial enzyme manufacturer in the world.
Novo Nordisk’s A shares are owned by the Novo Nordisk Foundation, the company’s foundation that takes care of financial grants to social, humanitarian and scientific objectives. The company’s B shares are traded in the stock exchanges of Zürich, London and Copenhagen.